Replies to post #241822 on Biotech Values

[DewDiligence]

SYRS acquires TYME for ~$0.39/sh in stock—a 44% premium to Friday’s close:

https://finance.yahoo.com/news/syros-raise-approximately-190-million-110000910.html

Following its failure in pancreatic cancer (#msg-167645887), TYME became a shell company with significant cash (#msg-168370010); hence, this buyout is essentially a financing transaction for SYRS. The deal value (excluding a separate financing transaction by SYRS announced today) is about $70M.